Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: a multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression

Paik, Jin Ho; Koh, Jiwon; Han, Bogyeong; Kim, Sehui; Lee, Ki Rim; Lee, Sejoon; Lee, Jeong-Ok; Kim, Tae Min; Kim, Wook Youn; Jeon, Yoon Kyung

doi:10.1016/j.humpath.2022.12.003

Cited by 3 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a diagnostic marker for nTFHL, CXCR5, and PD-1 showed the highest sensitivity, whereas CD10 and BCL6 exhibited high specificity but less sensitivity. AITL expressed more Tfh markers than PTCL-Tfh (average, 3.6 and 3.1), which is consistent with a previous report [ 25 ]. TCF1 expression was positively correlated with CXCR5 (Pearson’s r = 0.317, p = .026) and ICOS expression (Pearson’s r = 0.386, p = .006).…”

Section: Resultssupporting

confidence: 92%

“…For example, genetic mutations in epigenetic modifiers (i.e., DNMT3A and TET2 ) and RHOA , are shared, whereas IDH R172 mutations are considered exclusive to AITL [ 9 , 27 ]. PTCL-Tfh/nTFHL-NOS could be differentiated from PTCL-NOS based on Tfh marker expression, and approximately 40%–63% of cases previously diagnosed as PTCL-NOS are now deemed to be PTCL-Tfh/nTFHL-NOS [ 25 , 27 ]. Clinical studies indicated that nTFHL showed improved responsiveness to treatment involving epigenetic modifiers, such as histone deacetylase inhibitors and demethylating agents, compared to PTCL-NOS [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…The patients’ diagnoses were reviewed and classified based on the revised 4th and 5th WHO classification guidelines (WHO4R and WHO5, respectively). Some of the patients were included in our previous studies [ 25 , 26 ]. All cases were classified as having AITL (i.e., nTFHL-AI by WHO5), PTCL-Tfh (i.e., nTFHL-NOS by WHO5), or PTCL-NOS (i.e., PTCL-NOS by WHO5).…”

Section: Methodsmentioning

confidence: 99%

“…Immunostaining was performed using a Ventana Benchmark XT (Ventana Medical Systems, Tucson, AZ, USA) or a Bond-Max Autostainer (Leica Microsystems, Melbourne, Australia). The expression of Tfh markers (CD10, BCL6, PD-1, CXCR5, and ICOS) in CD3+ cells were considered positive if they were above 10% [ 25 ]. According to the IHC subclassification algorithm in PTCL-NOS [ 20 ], TBX21 and CXCR3 were considered positive above a 20% threshold, and GATA3 and CCR4 were considered positive beyond a 50% cutoff of CD3+ cells.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified

Han,

Lim,

Yim

et al. 2024

J Pathol Transl Med

Self Cite

View full text Add to dashboard Cite

Background: The classification of nodal peripheral T-cell lymphoma (PTCL) has evolved according to histology, cell-of-origin, and genetic alterations. However, the comprehensive expression pattern of follicular helper T-cell (Tfh) markers, T-cell factor-1 (TCF1), and Th1- and Th2-like molecules in nodal PTCL is unclear.Methods: Eighty-two cases of nodal PTCL were classified into 53 angioimmunoblastic T-cell lymphomas (AITLs)/nodal T-follicular helper cell lymphoma (nTFHL)-AI, 18 PTCLs-Tfh/nTFHL–not otherwise specified (NOS), and 11 PTCLs-NOS according to the revised 4th/5th World Health Organization classifications. Immunohistochemistry for TCF1, TBX21, CXCR3, GATA3, and CCR4 was performed.Results: TCF1 was highly expressed in up to 68% of patients with nTFHL but also in 44% of patients with PTCL-NOS (p > .05). CXCR3 expression was higher in AITLs than in non-AITLs (p = .035), whereas GATA3 expression was higher in non-AITL than in AITL (p = .007) and in PTCL-Tfh compared to AITL (p = .010). Of the cases, 70% of AITL, 44% of PTCLTfh/ nTFHL-NOS, and 36% of PTCL-NOS were subclassified as the TBX21 subtype; and 15% of AITL, 38% of PTCL-Tfh/nTFHL-NOS, and 36% of PTCL-NOS were subclassified as the GATA3 subtype. The others were an unclassified subtype. CCR4 expression was associated with poor progression-free survival (PFS) in patients with PTCL-Tfh (p < .001) and nTFHL (p = .023). The GATA3 subtype showed poor overall survival in PTCL-NOS compared to TBX21 (p = .046) and tended to be associated with poor PFS in patients with non-AITL (p = .054).Conclusions: The TBX21 subtype was more prevalent than the GATA3 subtype in AITL. The GATA3 subtype was associated with poor prognosis in patients with non-AITL and PTCL-NOS.

show abstract

Section: Resultssupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified

Han,

Lim,

Yim

et al. 2024

J Pathol Transl Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…and irregular follicular dendritic cell(FDC) proliferative foci which often surround high endothelial blood vessels. However, FDC proliferative foci are difficult to identify under light microscopy and require immunohistochemical labeling of CD21 to identify proliferative follicular dendritic cells [6,13].…”

Section: Introductionmentioning

confidence: 99%